• DOI:10.1111/liv.12098
Corpus ID: 19338115

Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US

@article{Sugimoto2013HepatocellularCT,
  title={Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US},
  author={K. Sugimoto and F. Moriyasu and K. Saito and N. Rognin and N. Kamiyama and Yoshihiro Furuichi and Y. Imai},
  journal={Liver International},
  year={2013},
  volume={33},
  pages={605 - 615}
}

K. Sugimoto, F. Moriyasu, +4 authors Y. Imai

Published 2013

Medicine

Liver International

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed

Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib. To evaluate the usefulness of dynamic contrast‐enhanced ultrasound (DCE‐US) for the early prediction of tumour response and major AEs in HCC patients.